Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Muvalaplin (LY3473329) in Renal Impairment
NCT05778864Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of muvalaplin in elevated lipoprotein(a) (Lp(a)) (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area under the concentration versus time curve from time zero to infinity, Area under the concentration versus time curve from time zero to last time point and 1 more. Started Mar 2023; status: completed.
02
Drugs
muvalaplin
03
Conditions
elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT05778864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05778864.